Supplementary Appendix 2 from Stool Bacteriomic Profiling in Patients with Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor–Tyrosine Kinase Inhibitors

MLA

Paul Frankel, et al. Supplementary Appendix 2 from Stool Bacteriomic Profiling in Patients with Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor–Tyrosine Kinase Inhibitors. Mar. 2023. EBSCOhost, https://doi.org/10.1158/1078-0432.22461341.v1.

APA

Paul Frankel, Courtney Carmichael, JoAnn Hsu, Marcin Kortylewski, Hanjun Qin, Xiwei Wu, Sierra M. Li, & Sumanta K. Pal. (2023). Supplementary Appendix 2 from Stool Bacteriomic Profiling in Patients with Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor–Tyrosine Kinase Inhibitors. https://doi.org/10.1158/1078-0432.22461341.v1

Chicago

Paul Frankel, Courtney Carmichael, JoAnn Hsu, Marcin Kortylewski, Hanjun Qin, Xiwei Wu, Sierra M. Li, and Sumanta K. Pal. 2023. “Supplementary Appendix 2 from Stool Bacteriomic Profiling in Patients with Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor–Tyrosine Kinase Inhibitors,” March. doi:10.1158/1078-0432.22461341.v1.